Androgen mediated translational and postranslational regulation of IGFBP-2 in androgen-sensitive LNCAP human prostate cancer cells

American Journal of Translational Research

Volumn 2, Issue 2, 2010, Pages 200-208

  DeGraff, David J ^a   Aguiar, Adam A ^a   Chen, Qian ^a   Adams, Lisa K ^b   Williams, B Jill ^b   Sikes, Robert A ^a  

^a UNIVERSITY OF DELAWARE   (United States)

^b Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

Androgen; Growth factor; High density culture; Insulin like growth factor binding protein; Prostate cancer; Regulation; Serine protease

Indexed keywords

ANDROGEN; MESSENGER RNA; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 2;

ABLATION THERAPY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC ASSOCIATION; HORMONE ACTION; HUMAN; HUMAN CELL; MALE; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; REGULATORY MECHANISM; RNA ANALYSIS; STEADY STATE; TRANSLATION REGULATION;

EID: 77953414581     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer 2002;2 (5):389-396.
2. Solomon MH, McHugh TA, Dorr RP, Lee F, Siders DB. Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy. Clin Invest Med 1993;16(6):532-538.
3. Schilling D, Gakis G, Bokeler U, Stenzl A, Kuczyk MA, Merseburger AS. [Secondary hormonal ablation in hormone-independent prostate cancer.]. Urologe A 2009;48(2):183-190.
4. Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev 2000(2):CD001526.
5. Gleave M, Miyake H, Chi K. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemother Pharmacol 2005; 56 Suppl 1:47-57.
6. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002;23(6):824-854.
7. Pollak MN. Insulin-like growth factors and neoplasia. Novartis Found Symp 2004; 262:84-98; discussion 98-107, 265-108.
8. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28(1):20-47.
9. DeGraff DJ, Aguiar AA, Sikes RA. Evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions. Am J Transl Res 2009;1(2):115-130.
10. Moore MG, Wetterau LA, Francis MJ, Peehl DM, Cohen P. Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int J Cancer 2003;105(1):14-19.
11. Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, Miyake H, Gleave ME. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 2003;63(13):3575-3584.
12. Degraff DJ, Malik M, Chen Q, Miyako K, Rejto L, Aguiar AA, Bancroft DR, Cohen P, Sikes RA. Hormonal regulation of IGFBP-2 proteolysis is attenuated with progression to androgen insensitivity in the LNCaP progression model. J Cell Physiol 2007;213(1):261-268.
13. Rubin J, Chung LW, Fan X, Zhu L, Murphy TC, Nanes MS, Rosen CJ. Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis. Prostate 2004;58(1):41-49.
14. Rubin J, Fan X, Rahnert J, Sen B, Hsieh CL, Murphy TC, Nanes MS, Horton LG, Beamer WG, Rosen CJ. IGF-I secretion by prostate carcinoma cells does not alter tumor-bone cell interactions in vitro or in vivo. Prostate 2006;66(8):789-800.
15. Inman BA, Harel F, Audet JF, Meyer F, Douville P, Fradet Y, Lacombe L. Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. Eur Urol 2005;47(5):695-702.
16. Gleave M, Jansen B. Clusterin and IGFBPs as antisense targets in prostate cancer. Ann N Y Acad Sci 2003;1002:95-104.
17. DeGraff DJ. Implications for the androgenic regulation of IGFBP-2 in the development of metastatic and androgen independent prostate cancer [Thesis Dissertation]. Newark: University of Delaware; 2008. 144 p.
18. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA. The LNCaP cell line--a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980;37:115-132.
19. Chang SM, Chung LW. Interaction between prostatic fibroblast and epithelial cells in culture: role of androgen. Endocrinology 1989;125 (5):2719-2727.
20. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 2000;44(2):91-103 Jul 101;144 (102).
21. Chen Q, Watson JT, Marengo SR, Decker KS, Coleman I, Nelson PS, Sikes RA. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo. Cancer Lett 2006;244(2):274-288.
22. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004;61 (4):332-353.
23. Goossens K, Esquenet M, Swinnen JV, Manin M, Rombauts W, Verhoeven G. Androgens decrease and retinoids increase the expression of insulinlike growth factor-binding protein-3 in LNcaP prostatic adenocarcinoma cells. Mol Cell Endocrinol 1999;155(1-2):9-18.
24. Arnold JT, Le H, McFann KK, Blackman MR. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Am J Physiol Endocrinol Metab 2005;288(3):E573-584.
25. Martin JL, Pattison SL. Insulin-like growth factor binding protein-3 is regulated by dihydrotestosterone and stimulates deoxyribonucleic acid synthesis and cell proliferation in LNCaP prostate carcinoma cells. Endocrinology 2000;141 (7):2401-2409.
26. Binkert C, Margot JB, Landwehr J, Heinrich G, Schwander J. Structure of the human insulin-like growth factor binding protein-2 gene. Mol Endocrinol 1992;6(5):826-836.
27. Epner DE, Sawa A and Isaacs JT. Glyceraldehyde-3-phosphate dehydrogenase expression during apoptosis and proliferation of rat ventral prostate. Biol Reprod 1999; 61: 687-691.
28. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 2003;54(4):249-257.